Itraconazole therapy in aspergillosis: study in 49 patients.
Itraconazole, 200 to 400 mg once daily, was administered to 49 patients with different types of aspergillosis: pulmonary aspergilloma (14 patients), chronic necrotizing pulmonary aspergillosis (14), and invasive aspergillosis (21). Itraconazole was prescribed alone or in combination or after treatment with amphotericin B and flucytosine. Of 14 aspergilloma patients, 2 were cured and 8 had symptomatic improvement. In chronic necrotizing pulmonary aspergillosis, 7 of 14 patients were cured and 6 improved significantly. In invasive aspergillosis treatment failed in 6 patients and 15 were cured. Itraconazole can be an alternative to amphotericin B in the treatment of invasive aspergillosis and chronic necrotizing pulmonary aspergillosis. In aspergilloma itraconazole may be useful in inoperable cases.
Dupont
B
B
Unité de Mycologie, Hôpital de l'Institut Pasteur, Paris, France.
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D004660:Encephalitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008297:Male; D015523:Maxillary Sinusitis / Q000188:drug therapy; D008875:Middle Aged; D012008:Recurrence
D000935:Antifungal Agents; D017964:Itraconazole; D007654:Ketoconazole